ENDRA Life Sciences Inc. SEC filings NDRA
ENDRA Life Sciences Inc. has 544 filings in SEC EDGAR's recent list, going back to Aug 9, 2016. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 28, 2025 | — |
| DEF 14A | Proxy statement | Oct 28, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 17, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Sep 17, 2024 | — |
| DEF 14A | Proxy statement | Sep 16, 2024 | Sep 6, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 6, 2024 | Sep 6, 2024 |
| DEFA14A | Additional proxy material | Jul 17, 2024 | — |
| DEFA14A | Additional proxy material | Jun 25, 2024 | — |
| DEF 14A | Proxy statement | Jun 25, 2024 | Aug 6, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 12, 2024 | Jun 11, 2024 |
| DEFA14A | Additional proxy material | Jul 25, 2023 | — |
| DEFA14A | Additional proxy material | Jul 6, 2023 | — |
| DEFA14A | Additional proxy material | May 24, 2023 | — |
| DEF 14A | Proxy statement | May 24, 2023 | Jul 6, 2023 |
| DEFA14A | Additional proxy material | Oct 17, 2022 | — |
| DEF 14A | Proxy statement | Oct 17, 2022 | Nov 29, 2022 |
| PRE 14A | Preliminary proxy statement | Sep 27, 2022 | Nov 29, 2022 |
| DEFA14A | Additional proxy material | Jun 21, 2022 | — |
| DEFA14A | Additional proxy material | May 17, 2022 | — |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 2, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 22, 2022 | Apr 21, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2021 | — |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 8, 2021 |
| DEFA14A | Additional proxy material | Aug 10, 2020 | — |
| DEF 14A | Proxy statement | Aug 3, 2020 | Aug 13, 2020 |
| PRE 14A | Preliminary proxy statement | Jul 22, 2020 | Jul 22, 2020 |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 16, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2020 | Jun 16, 2020 |
| DEF 14A | Proxy statement | Apr 15, 2019 | May 16, 2019 |
| DEF 14A | Proxy statement | May 10, 2018 | Jun 12, 2018 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- NDRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ann Arbor, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1681682
- Former names
- Endra Inc. (until Sep 21, 2016)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.